Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totaling 3,807 shares, a drop of 42.4% from the September 15th total of 6,607 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 63,910 shares, the short-interest ratio is presently 0.1 days.
Regentis Biomaterials Trading Up 2.0%
NYSEAMERICAN:RGNT traded up $0.03 during trading hours on Thursday, hitting $1.54. The company’s stock had a trading volume of 12,398 shares, compared to its average volume of 1,756,675. Regentis Biomaterials has a 52-week low of $1.23 and a 52-week high of $15.50. The business’s 50-day moving average is $1.92 and its two-hundred day moving average is $2.50.
Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last announced its quarterly earnings results on Friday, September 11th. The company reported ($0.22) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Regentis Biomaterials
An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent reporting period.
Regentis Biomaterials Company Profile
Regentis Biomaterials Ltd. is an Israel-based biotechnology company focused on developing biomaterial-based solutions for the repair and regeneration of damaged cartilage. The company’s work is aimed primarily at orthopedic applications, including the treatment of focal cartilage defects in the knee.
Regentis’ lead product is GelrinC, a synthetic, cell-free hydrogel implant designed to fill cartilage lesions and support the formation of new tissue. The implant is intended to be delivered during a minimally invasive procedure and gradually integrate with the surrounding joint environment as the repair process progresses.
The company’s activities center on research, clinical development, regulatory advancement and potential commercialization of its cartilage-repair technology.
Featured Articles
- Five stocks we like better than Regentis Biomaterials
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
